Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.

Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.

Item
http://www.wikidata.org/entity/Q35105844
Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical TrialPhenotype, Genotype, and Drug Resistance in Subtype C HIV-1 InfectionFactors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South AfricaGenetic Variability of HIV-1 for Drug Resistance Assay Development.Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.Computer-aided discovery of anti-HIV agents.In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection.Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitorsRole of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing
P2860

Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.

Item
http://www.wikidata.org/entity/Q35105844
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Impact of drug resistance-asso ...... erse transcriptase inhibitors.
@ast
Impact of drug resistance-asso ...... erse transcriptase inhibitors.
@en
type
label
Impact of drug resistance-asso ...... erse transcriptase inhibitors.
@ast
Impact of drug resistance-asso ...... erse transcriptase inhibitors.
@en
prefLabel
Impact of drug resistance-asso ...... erse transcriptase inhibitors.
@ast
Impact of drug resistance-asso ...... erse transcriptase inhibitors.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Impact of drug resistance-asso ...... erse transcriptase inhibitors.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932